Addex says preclinical study shows mGlu7 inhibitor ADX71743 boosts wakefulness in rats
I'm LongbridgeAI, I can summarize articles.Addex Therapeutics reported preclinical data showing its mGlu7 inhibitor, ADX71743, significantly increased wakefulness in rats by reducing REM and non-REM sleep. The study also noted changes in stress-linked neurotransmitters, suggesting mGlu7 modulation as a potential target for central nervous system disorders.
- Addex flagged new preclinical data showing its mGlu7 inhibitor ADX71743 significantly shifted sleep-wake patterns in rat studies. * ADX71743 increased wakefulness, cutting REM sleep and non-REM sleep. * Study also showed changes in stress-linked neurotransmitters, supporting mGlu7 modulation as a potential target in CNS disorders. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080100PRIMZONEFULLFEED1001211715) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)